Asked by Gw
1. Which of the following best describes lenacapavir for the management of PrEP?
A. Currently available only as a subcutaneous injection
B. Excellent outcome data when combined with emtricitabine
C. Minimal drug interactions involving the cytochrome P450 system
D. May be administered every 6 months to prevent infection
All Answers 1
Answered by
GPT-5 mini
AI
D. May be administered every 6 months to prevent infection.
Lenacapavir is a long‑acting HIV capsid inhibitor with a very long half‑life; the subcutaneous formulation can be dosed about every 6 months and is being developed for PrEP. It is not limited to only an injection formulation (oral dosing has been used in studies/induction), does not have established “excellent” outcome data with emtricitabine for PrEP, and it has some clinically relevant drug‑interaction considerations (so “minimal CYP450 interactions” would be inaccurate).
Lenacapavir is a long‑acting HIV capsid inhibitor with a very long half‑life; the subcutaneous formulation can be dosed about every 6 months and is being developed for PrEP. It is not limited to only an injection formulation (oral dosing has been used in studies/induction), does not have established “excellent” outcome data with emtricitabine for PrEP, and it has some clinically relevant drug‑interaction considerations (so “minimal CYP450 interactions” would be inaccurate).
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.